Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28and let-7 miRNAs in oral squamous cell carcinoma

Authors: Katharina Anna Sterenczak, Andre Eckardt, Andreas Kampmann, Saskia Willenbrock, Nina Eberle, Florian Länger, Sven Kleinschmidt, Marion Hewicker-Trautwein, Hans Kreipe, Ingo Nolte, Hugo Murua Escobar, Nils Claudius Gellrich

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Humans and dogs are affected by squamous cell carcinomas of the oral cavity (OSCC) in a considerably high frequency. The high mobility group A2 (HMGA2) protein was found to be highly expressed in human OSCC and its expression was suggested to act as a useful predictive and prognostic tool in clinical management of oral carcinomas. Herein the expression of HMGA2 and its sister gene HMGA1 were analysed within human and canine OSCC samples. Additionally, the HMGA negatively regulating miRNAs of the let-7 family as well as the let-7 regulating gene Lin28 were also comparatively analysed. Deregulations of either one of these members could affect the progression of human and canine OSCC.

Methods

Expression levels of HMGA1, HMGA2, Lin28, let-7a and mir-98 were analysed via relative qPCR in primary human and canine OSCC, thereof derived cell lines and non-neoplastic samples. Additionally, comparative HMGA2 protein expression was analysed by immunohistochemistry.

Results

In both species, a significant up-regulation of the HMGA2 gene was found within the neoplastic samples while HMGA1 expression did not show significant deregulations. Comparative analyses showed down-regulation of mir-98 in human samples and up-regulation of let-7a and mir-98 in canine neoplastic samples. HMGA2 immunostainings showed higher intensities within the invasive front of the tumours than in the centre of the tumour in both species.

Conclusions

HMGA2 could potentially serve as tumour marker in both species while HMGA1 might play a minor role in OSCC progression. Comparative studies indicate an inverse correlation of HMGA2 and mir-98 expression in human samples whereas in dogs no such characteristic could be found.
Appendix
Available only for authorised users
Literature
1.
go back to reference Petersen PE: Oral cancer prevention and control–the approach of the World Health Organization. Oral Oncol. 2009, 45 (4–5): 454-460.CrossRefPubMed Petersen PE: Oral cancer prevention and control–the approach of the World Health Organization. Oral Oncol. 2009, 45 (4–5): 454-460.CrossRefPubMed
2.
go back to reference Mannarini L, Kratochvil V, Calabrese L, Gomes Silva L, Morbini P, Betka J, Benazzo M: Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital. 2009, 29 (3): 119-126.PubMedPubMedCentral Mannarini L, Kratochvil V, Calabrese L, Gomes Silva L, Morbini P, Betka J, Benazzo M: Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital. 2009, 29 (3): 119-126.PubMedPubMedCentral
3.
go back to reference Withrow S, Vail D: Withrow and MacEwen’s Small Animal Clinical Oncology. 2007, St. Louis: Saunders Elsevier, 4 Withrow S, Vail D: Withrow and MacEwen’s Small Animal Clinical Oncology. 2007, St. Louis: Saunders Elsevier, 4
4.
go back to reference Mallet Y, Avalos N, Le Ridant AM, Gangloff P, Moriniere S, Rame JP, Poissonnet G, Makeieff M, Cosmidis A, Babin E, Barry B, Fournier C: Head and neck cancer in young people: a series of 52 SCCs of the oral tongue in patients aged 35 years or less. Acta Otolaryngol. 2009, 129 (12): 1503-1508. 10.3109/00016480902798343.CrossRefPubMed Mallet Y, Avalos N, Le Ridant AM, Gangloff P, Moriniere S, Rame JP, Poissonnet G, Makeieff M, Cosmidis A, Babin E, Barry B, Fournier C: Head and neck cancer in young people: a series of 52 SCCs of the oral tongue in patients aged 35 years or less. Acta Otolaryngol. 2009, 129 (12): 1503-1508. 10.3109/00016480902798343.CrossRefPubMed
5.
go back to reference Kokemueller H, Rana M, Rublack J, Eckardt A, Tavassol F, Schumann P, Lindhorst D, Ruecker M, Gellrich NC: The Hannover experience: surgical treatment of tongue cancer–a clinical retrospective evaluation over a 30 years period. Head Neck Oncol. 2011, 3: 27-10.1186/1758-3284-3-27.CrossRefPubMedPubMedCentral Kokemueller H, Rana M, Rublack J, Eckardt A, Tavassol F, Schumann P, Lindhorst D, Ruecker M, Gellrich NC: The Hannover experience: surgical treatment of tongue cancer–a clinical retrospective evaluation over a 30 years period. Head Neck Oncol. 2011, 3: 27-10.1186/1758-3284-3-27.CrossRefPubMedPubMedCentral
6.
go back to reference Nao EE, Dassonville O, Poissonnet G, Chamorey E, Pierre CS, Riss JC, Vincent N, Peyrade F, Benezery K, Chemaly L, Sudaka A, Marcy PY, Vallicioni J, Demard F, Santini J, Bozec A: Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. Acta Otolaryngol. 2011, 131 (10): 1104-1109. 10.3109/00016489.2011.593044.CrossRefPubMed Nao EE, Dassonville O, Poissonnet G, Chamorey E, Pierre CS, Riss JC, Vincent N, Peyrade F, Benezery K, Chemaly L, Sudaka A, Marcy PY, Vallicioni J, Demard F, Santini J, Bozec A: Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. Acta Otolaryngol. 2011, 131 (10): 1104-1109. 10.3109/00016489.2011.593044.CrossRefPubMed
7.
go back to reference Williams MD: Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol. 2010, 4 (1): 62-69. 10.1007/s12105-010-0166-6.CrossRefPubMedPubMedCentral Williams MD: Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol. 2010, 4 (1): 62-69. 10.1007/s12105-010-0166-6.CrossRefPubMedPubMedCentral
8.
go back to reference Cleynen I, Van de Ven WJ: The HMGA proteins: a myriad of functions (Review). Int J Oncol. 2008, 32 (2): 289-305.PubMed Cleynen I, Van de Ven WJ: The HMGA proteins: a myriad of functions (Review). Int J Oncol. 2008, 32 (2): 289-305.PubMed
9.
go back to reference Joetzke AE, Sterenczak KA, Eberle N, Wagner S, Soller JT, Nolte I, Bullerdiek J, Murua Escobar H, Simon D: Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases. Vet Comp Oncol. 2010, 8 (2): 87-95. 10.1111/j.1476-5829.2010.00207.x.CrossRefPubMed Joetzke AE, Sterenczak KA, Eberle N, Wagner S, Soller JT, Nolte I, Bullerdiek J, Murua Escobar H, Simon D: Expression of the high mobility group A1 (HMGA1) and A2 (HMGA2) genes in canine lymphoma: analysis of 23 cases and comparison to control cases. Vet Comp Oncol. 2010, 8 (2): 87-95. 10.1111/j.1476-5829.2010.00207.x.CrossRefPubMed
10.
go back to reference Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I, Bullerdiek J: HMGA2 expression in a canine model of prostate cancer. Cancer Genet Cytogenet. 2007, 177 (2): 98-102. 10.1016/j.cancergencyto.2007.06.008.CrossRefPubMed Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I, Bullerdiek J: HMGA2 expression in a canine model of prostate cancer. Cancer Genet Cytogenet. 2007, 177 (2): 98-102. 10.1016/j.cancergencyto.2007.06.008.CrossRefPubMed
11.
go back to reference Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004, 64 (6): 2024-2029. 10.1158/0008-5472.CAN-03-1855.CrossRefPubMed Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004, 64 (6): 2024-2029. 10.1158/0008-5472.CAN-03-1855.CrossRefPubMed
12.
go back to reference Rho YS, Lim YC, Park IS, Kim JH, Ahn HY, Cho SJ, Shin HS: High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007, 127 (1): 76-81. 10.1080/00016480600740571.CrossRefPubMed Rho YS, Lim YC, Park IS, Kim JH, Ahn HY, Cho SJ, Shin HS: High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007, 127 (1): 76-81. 10.1080/00016480600740571.CrossRefPubMed
13.
go back to reference Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007, 6: 5-10.1186/1476-4598-6-5.CrossRefPubMedPubMedCentral Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ: High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007, 6: 5-10.1186/1476-4598-6-5.CrossRefPubMedPubMedCentral
14.
go back to reference Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y: Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol. 2010, 41 (4): 493-502. 10.1016/j.humpath.2009.08.022.CrossRefPubMed Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y: Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol. 2010, 41 (4): 493-502. 10.1016/j.humpath.2009.08.022.CrossRefPubMed
15.
go back to reference Rahman MM, Qian ZR, Wang EL, Sultana R, Kudo E, Nakasono M, Hayashi T, Kakiuchi S, Sano T: Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer. 2009, 100 (3): 501-510. 10.1038/sj.bjc.6604883.CrossRefPubMedPubMedCentral Rahman MM, Qian ZR, Wang EL, Sultana R, Kudo E, Nakasono M, Hayashi T, Kakiuchi S, Sano T: Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer. 2009, 100 (3): 501-510. 10.1038/sj.bjc.6604883.CrossRefPubMedPubMedCentral
16.
go back to reference Heo I, Joo C, Cho J, Ha M, Han J, Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell. 2008, 32 (2): 276-284. 10.1016/j.molcel.2008.09.014.CrossRefPubMed Heo I, Joo C, Cho J, Ha M, Han J, Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell. 2008, 32 (2): 276-284. 10.1016/j.molcel.2008.09.014.CrossRefPubMed
17.
go back to reference Newman MA, Thomson JM, Hammond SM: Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA. 2008, 14 (8): 1539-1549. 10.1261/rna.1155108.CrossRefPubMedPubMedCentral Newman MA, Thomson JM, Hammond SM: Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA. 2008, 14 (8): 1539-1549. 10.1261/rna.1155108.CrossRefPubMedPubMedCentral
18.
19.
go back to reference Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 2008, 14 (9): 400-409. 10.1016/j.molmed.2008.07.001.CrossRefPubMed Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 2008, 14 (9): 400-409. 10.1016/j.molmed.2008.07.001.CrossRefPubMed
20.
21.
go back to reference Wu T, Jia J, Xiong X, He H, Bu L, Zhao Z, Huang C, Zhang W: Increased expression of Lin28B associates with poor prognosis in patients with oral squamous cell carcinoma. PLoS One. 2013, 8 (12): e83869-10.1371/journal.pone.0083869.CrossRefPubMedPubMedCentral Wu T, Jia J, Xiong X, He H, Bu L, Zhao Z, Huang C, Zhang W: Increased expression of Lin28B associates with poor prognosis in patients with oral squamous cell carcinoma. PLoS One. 2013, 8 (12): e83869-10.1371/journal.pone.0083869.CrossRefPubMedPubMedCentral
22.
go back to reference Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D, Murua Escobar H: High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res. 2010, 30 (12): 5043-5048.PubMed Sterenczak KA, Joetzke AE, Willenbrock S, Eberle N, Lange S, Junghanss C, Nolte I, Bullerdiek J, Simon D, Murua Escobar H: High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res. 2010, 30 (12): 5043-5048.PubMed
23.
go back to reference Adams JC: Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem. 1992, 40 (10): 1457-1463. 10.1177/40.10.1527370.CrossRefPubMed Adams JC: Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem. 1992, 40 (10): 1457-1463. 10.1177/40.10.1527370.CrossRefPubMed
24.
go back to reference Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30 (9): e36-10.1093/nar/30.9.e36.CrossRefPubMedPubMedCentral Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30 (9): e36-10.1093/nar/30.9.e36.CrossRefPubMedPubMedCentral
25.
go back to reference Chang JY, Wright JM, Svoboda KK: Signal transduction pathways involved in epithelial-mesenchymal transition in oral cancer compared with other cancers. Cells Tissues Organs. 2007, 185 (1–3): 40-47.CrossRefPubMed Chang JY, Wright JM, Svoboda KK: Signal transduction pathways involved in epithelial-mesenchymal transition in oral cancer compared with other cancers. Cells Tissues Organs. 2007, 185 (1–3): 40-47.CrossRefPubMed
26.
go back to reference Imai K: Epitehlial-mesenchymal transition and progression of oral carcinomas. Cancer Therapy. 2004, 2: 6- Imai K: Epitehlial-mesenchymal transition and progression of oral carcinomas. Cancer Therapy. 2004, 2: 6-
28.
go back to reference Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, Chu PY, Lo WL: MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011, 47 (3): 202-210. 10.1016/j.oraloncology.2010.12.001.CrossRefPubMed Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, Tseng LM, Chiou SH, Yen SH, Chou MY, Chu PY, Lo WL: MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011, 47 (3): 202-210. 10.1016/j.oraloncology.2010.12.001.CrossRefPubMed
29.
go back to reference Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu T, Lu XM: Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep. 2012, 39 (2): 1239-1246. 10.1007/s11033-011-0854-7.CrossRefPubMed Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu T, Lu XM: Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep. 2012, 39 (2): 1239-1246. 10.1007/s11033-011-0854-7.CrossRefPubMed
30.
go back to reference Bianchini L, Saada E, Gjernes E, Marty M, Haudebourg J, Birtwisle-Peyrottes I, Keslair F, Chignon-Sicard B, Chamorey E, Pedeutour F: Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer. 2011, 50 (6): 442-455. 10.1002/gcc.20869.CrossRefPubMed Bianchini L, Saada E, Gjernes E, Marty M, Haudebourg J, Birtwisle-Peyrottes I, Keslair F, Chignon-Sicard B, Chamorey E, Pedeutour F: Let-7 microRNA and HMGA2 levels of expression are not inversely linked in adipocytic tumors: analysis of 56 lipomas and liposarcomas with molecular cytogenetic data. Genes Chromosomes Cancer. 2011, 50 (6): 442-455. 10.1002/gcc.20869.CrossRefPubMed
Metadata
Title
HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28and let-7 miRNAs in oral squamous cell carcinoma
Authors
Katharina Anna Sterenczak
Andre Eckardt
Andreas Kampmann
Saskia Willenbrock
Nina Eberle
Florian Länger
Sven Kleinschmidt
Marion Hewicker-Trautwein
Hans Kreipe
Ingo Nolte
Hugo Murua Escobar
Nils Claudius Gellrich
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-694

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine